Product nameCOLO205 whole cell lysate
Growth Properties: mixed, adherent and suspension
Tumor Stage: Dukes' type D
Disease: colorectal adenocarcinoma
Derived from metastatic site: ascites
Cellular Products: carcinoembryonic antigen (CEA) 1.5 to 4.1 ng/10 exp6 cells/10 days; keratin; interleukin 10 (IL-10, interleukin-10)
This is a recommended negative control for PD-L1 RabMAb (clone 28-8), ab205921
Tested applicationsSuitable for: WB, SDS-PAGEmore details
FormLyophilised:Add 100 µl distilled water to the sample. Final concentration is 2 mg/ml.
Storage instructionsShipped at 4°C. After reconstitution store at -20ºC. Avoid freeze / thaw cycles.
Storage bufferpH: 6.80
Constituents: 0.1% Bromophenol blue, 2% SDS, 10% Glycerol, 1.54% DTT, 0.79% Tris HCl
Concentration information loading...
PurityWhole Cell Lysate
This line was isolated in 1975 by T.U. Semple, et al. from ascitic fluid of a 70-year-old Caucasian male with carcinoma of the colon. The patient had been treated with 5-fluorouracil for 4-6 weeks before removal of the fluid specimen. The cells are CSAp negative (CSAp-). The line was derived from tissue from the same patient as COLO 201. The cells are positive for keratin by immunoperoxidase staining. COLO 205 cells express a 36000 dalton cell surface glycoprotein related to the GA733-2 tumor associated antigen.
Our Abpromise guarantee covers the use of ab95356 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration.|
|SDS-PAGE||Use at an assay dependent concentration.|
ab95356 has not yet been referenced specifically in any publications.